Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Feras, Khalil"'
Autor:
Renata Jończyk, Christoph Beuter, Beata Bulawa, Stefan Buller, Christoph Eibl, Christian Elling, Michael Gautrois, Jens Rengelshausen, Carsten Schmidt, Guido Thömmes, Feras Khalil
Publikováno v:
Journal of Pain Research. 15:3103-3114
Autor:
Renata, Jończyk, Christoph, Beuter, Beata, Bulawa, Stefan, Buller, Christoph, Eibl, Christian, Elling, Michael, Gautrois, Jens, Rengelshausen, Carsten, Schmidt, Guido, Thömmes, Feras, Khalil
Publikováno v:
Journal of pain research. 15
This prospective, open-label trial was conducted to fulfil a post-approval commitment made to the competent authorities to extend the indication of the strong opioid analgesic tapentadol hydrochloride oral solution (OS) to the pediatric population.Th
Autor:
Beata Bulawa, Mariëlle Eerdekens, Melanie Sohns, Feras Khalil, Christian Elling, Tatjana Radic
Publikováno v:
Journal of Pain Research
The opioid analgesic tapentadol was the first pain medication to be developed for the treatment of pain in children under a formal process established by the regulatory authorities. This article summarizes the outcomes of the pediatric development pr
Autor:
Thomas M. Tzschentke, Estelle Watson, Feras Khalil, Claudia Lefeber, Jan Freijer, Mariëlle Eerdekens, Siak Leng Choi
Publikováno v:
Journal of Pain Research. 13:3107-3123
Objective The main aim of this analysis was to characterize the pharmacokinetics (PK) of tapentadol in pediatric patients from birth to
Autor:
Nina Makowski, Milica Bajcetic, Holger Schwender, Feras Khalil, Ida Jovanovic, Jennifer Walsh, Stephanie Läer, Michiel Dalinghaus, Saskia N. de Wildt, Cristina Castro Díez, Marijke van der Meulen
Publikováno v:
Cardiology in the Young, 29(7):Pii s104795111900066, 869-876. Cambridge University Press
Cardiology in the Young, 29, 7, pp. 869-876
Cardiology in the Young, 29, 869-876
Cardiology in the Young, 29, 7, pp. 869-876
Cardiology in the Young, 29, 869-876
Background:Little evidence exists to support pharmacotherapeutic strategies for heart failure management in paediatrics. A recent Europe-wide survey suggests that this translates into substantial variability in clinical practice.Objective:To conduct
Autor:
Feras, Khalil, Siak Leng, Choi, Estelle, Watson, Thomas M, Tzschentke, Claudia, Lefeber, Mariëlle, Eerdekens, Jan, Freijer
Publikováno v:
Journal of Pain Research
Objective The main aim of this analysis was to characterize the pharmacokinetics (PK) of tapentadol in pediatric patients from birth to
Autor:
Cristina Castro Díez, Ida Jovanovic, Saskian de Wildt, Marijke van der Meulen, András Szatmári, Vanessa Swoboda, Stephanie Laeer, Michiel Dalinghaus, Milica Bajcetic, Johannes M.P.J. Breur, Michael Burch, Ingrid Klingmann, Florian B. Lagler, Feras Khalil
Publikováno v:
Archives of Disease in Childhood, 103, 1, pp. 106-109
Archives of Disease in Childhood, 103, 106-109
Archives of Disease in Childhood, 103, 106-109
A boy aged 1 year, recently diagnosed with dilated cardiomyopathy, has to be treated with enalapril according to the heart failure protocol. The physician wants to know which adverse events she can expect. What are the potential adverse events relate
Autor:
Jörg Breitkreutz, Florian B. Lagler, Feras Khalil, Stephanie Laeer, Anne Van Hecken, Jan de Hoon, B.B. Burckhardt, Ingrid Klingmann, Marissa Herbots
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(2)
The angiotensin-converting enzyme inhibitor enalapril is commonly used to treat chronic heart failure in children. Because some children are unable to swallow capsules or tablets, a new, age-appropriate, orodispersible minitablet (ODMT) containing 1
Autor:
Edgar Schuck, Yang Xu, Arian Emami Riedmaier, Haojing Rong, Rangaraj Narayanan, Pradeep Sharma, Felix Huth, Maud Beneton, Jing Lin, Ming Zheng, Iain Gardner, Yuan Chen, Masoud Jamei, Venkatesh Pilla Reddy, Christiane Collins, Mohamad Shebley, Jun Chen, Punam Sandhu, Shinji Yamazaki, Loeckie de Zwart, Malcolm Rowland, Nassim Djebli, Faraz Kazmi, Sheila Annie Peters, Yumi Cleary, Aarti Patel, Shu Pei Wu, Chirag Patel, Francois Bouzom, Aleksandrs Odinecs, Feras Khalil, Gemma L. Dickinson, Heidi J. Einolf, Kenta Yoshida
Publikováno v:
Shebley, M, Sandhu, P, Emami Riedmaier, A, Jamei, M, Narayanan, R, Patel, A, Peters, S A, Reddy, V P, Zheng, M, de Zwart, L, Beneton, M, Bouzom, F, Chen, J, Chen, Y, Cleary, Y, Collins, C, Dickinson, G L, Djebli, N, Einolf, H J, Gardner, I, Huth, F, Kazmi, F, Khalil, F, Lin, J, Odinecs, A, Patel, C, Rong, H, Schuck, E, Sharma, P, Wu, S P, Xu, Y, Yamazaki, S, Yoshida, K & Rowland, M 2018, ' Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions : A Consortium Perspective ', Clinical Pharmacology and Therapeutics . https://doi.org/10.1002/cpt.1013
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
This work provides a perspective on the qualification and verification of physiologically based pharmacokinetic (PBPK) platforms/models intended for regulatory submission based on the collective experience of the Simcyp Consortium members. Examples o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4695aa7ee7d1f810eac77f151fe62bd
https://doi.org/10.1002/cpt.1013
https://doi.org/10.1002/cpt.1013
Publikováno v:
Progress in Pediatric Cardiology. 39:37-41
Individualized medical therapy for children with heart muscle disease remains a challenge. Two innovative tools, physiologically based pharmacokinetic modeling and stem cell technology, have the potential to address these challenges. In this review,